# OnCo record epigenetic-progenitor-theory (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/epigenetic-progenitor-theory/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "epigenetic-progenitor-theory" ;
  schema:name "Epigenetic progenitor theory: cancer without a first mutation"@en ;
  schema:alternateName "epigenetic theory of cancer"@en, "epigenetic progenitor model"@en, "non-mutational origin of cancer"@en, "epigenetic origin of cancer"@en ;
  schema:description "The proposal that cancer begins not with a mutation but with a reversible change in how genes are switched on and off in a stem or progenitor cell, which then makes later mutations more likely and more dangerous. It explains cancers with almost no mutations and why cells can switch state under treatment, and it produced the epigenetic drugs used in blood cancers."@en ;
  schema:url <https://onco.cc/terms/epigenetic-progenitor-theory/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cancer_epigenetics> ;
  schema:citation <https://doi.org/10.1038/nrg1748>, <https://doi.org/10.1038/301089a0>, <https://doi.org/10.1038/nrg.2016.13>, <https://doi.org/10.1126/science.aal2380>, <https://doi.org/10.1038/nature13108> ;
  onco:tag "theory" ;
  onco:related <https://onco.cc/pathways/theories-of-cancer/>, <https://onco.cc/terms/somatic-mutation-theory/>, <https://onco.cc/terms/cancer-stem-cell-theory/>, <https://onco.cc/terms/hallmarks-synthesis/>, <https://onco.cc/terms/ageing-tissue-field-theory/>, <https://onco.cc/terms/metabolic-theory-of-cancer/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/terms/nonmutational-epigenetic-reprogramming/>, <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/drug-tolerant-persisters/>, <https://onco.cc/pathways/clonal-haematopoiesis/>, <https://onco.cc/terms/h3k27m/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/methylation-profiling/> ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/ependymoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/epigenetic-editing/>, <https://onco.cc/technologies/idh-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/idh/>, <https://onco.cc/targets/menin/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/vorasidenib/> ;
  onco:pathways <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/drug-tolerant-persisters/>, <https://onco.cc/pathways/clonal-haematopoiesis/> ;
  onco:people <https://onco.cc/people/stephen-baylin/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-feinberg-nature/>, <https://onco.cc/key-papers/paper-mack-nature/>, <https://onco.cc/key-papers/paper-feinberg-nat-rev-genet/>, <https://onco.cc/key-papers/paper-feinberg-nat-rev-genet-2006/>, <https://onco.cc/key-papers/paper-flavahan-science/> .